| |
All
|
BRCA1 or 2 mutation
|
|---|
|
Yes
|
No
|
|---|
|
Patients
|
120
|
12 (10 %)
|
108 (90 %)
|
|
Triple-negative
|
20 (17 %)
|
6 (50 %)
|
14 (13 %)*
|
|
ER&PR positive
|
67 (57 %)
|
3 (25 %)
|
64 (61 %)*
|
|
HER2 positive
|
27 (23 %)
|
0
|
27 (26 %)*
|
|
Histology
| | | |
|
Invasive Ductal Carcinoma (IDC)
|
98 (85 %)
|
11 (92 %)
|
87 (82 %)
|
|
Ductal Carcinoma In Situ (DCIS)
|
11 (9 %)
|
0
|
11 (10 %)
|
|
Invasive Lobular Carcinoma (ILC)
|
4 (3 %)
|
0
|
4 (4 %)
|
|
Other/rare
|
4 (3 %)
|
1 (8 %)
|
3 (3 %)
|
|
Age at diagnosis
|
50.6 ± 11.6
|
43.7 ± 11.8
|
51.4 ± 11.3*
|
|
Age at first menses
|
12.8 ± 1.6
|
12.3 ± 1.4
|
12.8 ± 1.6
|
|
Education
| | | |
|
High school diploma or less
|
95 (81 %)
|
8 (66 %)
|
87 (82 %)
|
|
Beyond high school
|
23 (19 %)
|
4 (34 %)
|
19 (18 %)
|
|
Household Income
| | | |
|
< $25,000
|
61 (60 %)
|
1 (10 %)
|
60 (65 %)
|
|
> $25,000
|
41 (40 %)
|
9 (90 %)
|
32 (35 %)
|
|
Family history of BRCA
|
42 (35 %)
|
6 (50 %)
|
36 (34 %)
|
- *Significantly different, P < 0.05
